Duke Discovery Yields Potential New Treatment for Gout

S, Wu R, Mellis S, Radin A. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled,monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis. 2009 Oct;68(10):1613-7.

Sundy JS. Gout management: let's get it right this time. Arthritis Rheum.

2008 Nov 15;59(11):1535-7.

Sundy JS, Becker MA, Baraf HS, Barkhuizen A, Moreland LW, Huang W, Waltrip

RW 2nd, Maroli AN, Horowitz Z; Pegloticase Phase 2 Study

InvestigatorsPegloticase Phase 2 Study Investigators, in addition to the

authors, were as follows: Asad Fraser, MD, Graves-Gilbert Clinic, Bowling

Green, Kentucky; Richard Furie, MD, North Shore-Long Island Jewish Health

System, Lake Success, New York; Arthur F. Kavanaugh, MD, University of

California, San Diego, La Jolla; Kelly D. Krohn, MD, Eli Lilly & Company,

Indianapolis, Indiana. Reduction of plasma urate levels following

treatment with multiple doses of pegloticase (polyethylene

glycol-conjugated uricase) in patients with treatment-failure gout:

Results of a phase II randomized study. Arthritis Rheum. 2008

Sep;58(9):2882-91.

Sundy JS, Hershfield MS. Uricase and other novel agents for the management

of patients with treatment-failure gout. Curr Rheumatol Rep. 2007

Jun;9(3):258-64.

Ganson NJ, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS. Control of

hyperuricemia in subjects with refractory gout, and induction of antibody

against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous

PEGylated urate oxidase. Arthritis Res Ther. 2006;8(1):R12.